Morepen Laboratories Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Morepen Laboratories heeft een totaal eigen vermogen van ₹11.1B en een totale schuld van ₹334.9M, wat de schuld-eigenvermogensverhouding op 3% brengt. De totale activa en totale passiva bedragen respectievelijk ₹15.6B en ₹4.5B. De EBIT Morepen Laboratories is ₹1.8B waardoor de rentedekking 65.5 is. Het heeft contanten en kortetermijnbeleggingen van ₹1.9B.
Belangrijke informatie
3.0%
Verhouding schuld/eigen vermogen
₹334.95m
Schuld
| Rente dekkingsratio | 65.5x |
| Contant | ₹1.86b |
| Aandelen | ₹11.10b |
| Totaal verplichtingen | ₹4.52b |
| Totaal activa | ₹15.62b |
Recente financiële gezondheidsupdates
Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?
Jun 13
Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly
Nov 23Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
Aug 10Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
May 21Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet
Jan 03
Recent updates
There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump
Aug 20Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)
Aug 09Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified
Jul 05Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?
Jun 13Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing
Apr 23Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly
Nov 23Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 22Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
Aug 10Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 21Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Apr 05Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?
Sep 14Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
May 21Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?
Mar 12Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay
Feb 22Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 07Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain
Jan 21Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet
Jan 03Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?
Dec 16Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Nov 28Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹10.9B ) MOREPENLAB } overtreffen de korte termijn passiva ( ₹4.1B ).
Langlopende schulden: De kortetermijnactiva MOREPENLAB ( ₹10.9B ) overtreffen de langetermijnschulden ( ₹453.2M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: MOREPENLAB heeft meer geld in kas dan de totale schuld.
Schuld verminderen: De schuld/eigen vermogen-ratio van MOREPENLAB is de afgelopen 5 jaar gedaald van 64.2% naar 3%.
Schuldendekking: De schuld van MOREPENLAB wordt goed gedekt door de operationele kasstroom ( 144.2% ).
Rentedekking: De rentebetalingen op de schuld van MOREPENLAB worden goed gedekt door EBIT ( 65.5 x dekking).